IRDye800CW
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IRDye800CW, covering 2026-03-10 to 2026-03-10. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 1]